Lyra Therapeutics, Inc. (LYRA)

Lyra Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 17, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Cap	1	14	300	100	57	147
Market Cap Growth	-95.56%	-95.49%	199.99%	76.22%	-61.53%	-
Enterprise Value	10.2	3.2	218.5	2.71	11.34	74.29
Last Close Price	0.35	10.32	262.00	157.00	218.00	570.00
PE Ratio	-	-0.14	-4.16	-1.72	-1.30	-4.40
PS Ratio	1.46	8.82	192.43	73.32	198.99	-
PB Ratio	-	1.17	3.35	1.24	1.65	1.98
P/TBV Ratio	-0.12	1.16	2.92	1.18	1.65	1.32
P/FCF Ratio	-	-0.19	-4.66	-2.29	-1.94	-6.43
P/OCF Ratio	-	-0.19	-4.74	-2.30	-2.20	-6.97
EV/Sales Ratio	17.00	2.09	140.24	1.99	39.80	-
EV/EBITDA Ratio	-	-0.03	-3.27	-0.05	-0.27	-3.36
EV/EBIT Ratio	-	-0.03	-3.26	-0.05	-0.26	-3.35
EV/FCF Ratio	-	-0.04	-3.40	-0.06	-0.39	-3.24
Debt / Equity Ratio	-6.17	2.61	0.24	0.01	0.01	0.02
Debt / EBITDA Ratio	-0.90	-0.36	-0.40	-0.04	-0.03	-0.11
Debt / FCF Ratio	-0.92	-0.47	-0.42	-0.05	-0.05	-0.11
Net Debt / Equity Ratio	-2.15	-0.53	-0.85	-1.18	-1.29	-0.97
Net Debt / EBITDA Ratio	-0.27	0.07	1.14	1.73	1.04	3.26
Net Debt / FCF Ratio	-0.27	0.09	1.18	2.20	1.52	3.15
Asset Turnover	0.01	0.01	0.01	0.02	0.00	0
Quick Ratio	2.33	3.21	5.24	6.77	2.51	15.27
Current Ratio	2.43	3.41	5.35	6.97	2.63	15.54
Return on Equity (ROE)	-906.88%	-184.99%	-73.67%	-96.08%	-79.98%	-54.09%
Return on Assets (ROA)	-64.14%	-92.18%	-53.10%	-68.30%	-64.28%	-46.37%
Return on Invested Capital (ROIC)	-168.36%	-390.34%	-482.94%	-5200.25%	-2140.61%	-1395.04%
Return on Capital Employed (ROCE)	-80.31%	-109.04%	-61.44%	-85.24%	-77.49%	-51.83%
Earnings Yield	-3750.08%	-692.83%	-24.05%	-58.28%	-76.83%	-22.72%
FCF Yield	-3882.12%	-535.03%	-21.46%	-43.58%	-51.50%	-15.55%
Buyback Yield / Dilution	-46.54%	-65.23%	-23.13%	-100.56%	-1.07%	-40.63%

Updated Nov 12, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q